GB0003225D0 - Models, methods and materials relating to clinical conditions associated with reactive oxygen species - Google Patents

Models, methods and materials relating to clinical conditions associated with reactive oxygen species

Info

Publication number
GB0003225D0
GB0003225D0 GBGB0003225.0A GB0003225A GB0003225D0 GB 0003225 D0 GB0003225 D0 GB 0003225D0 GB 0003225 A GB0003225 A GB 0003225A GB 0003225 D0 GB0003225 D0 GB 0003225D0
Authority
GB
United Kingdom
Prior art keywords
methods
models
conditions associated
oxygen species
reactive oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0003225.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0003225.0A priority Critical patent/GB0003225D0/en
Publication of GB0003225D0 publication Critical patent/GB0003225D0/en
Priority to PCT/GB2001/000571 priority patent/WO2001058462A2/en
Priority to AU2001232081A priority patent/AU2001232081A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)

Abstract

The present invention relates to a method for the preparation of an extract containing a vasoactive factor from a biological sample such as preeclamptic placenta or blood. The method comprises treating the sample with an alcohol solution of an organic acid, maintaining acidosis and minimising exposure of the extract to air.Compositions, methods and uses related to this extraction method are provided.
GBGB0003225.0A 2000-02-11 2000-02-11 Models, methods and materials relating to clinical conditions associated with reactive oxygen species Ceased GB0003225D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0003225.0A GB0003225D0 (en) 2000-02-11 2000-02-11 Models, methods and materials relating to clinical conditions associated with reactive oxygen species
PCT/GB2001/000571 WO2001058462A2 (en) 2000-02-11 2001-02-12 Models, methods and materials relating to clinical conditions associated with reactive oxygen species
AU2001232081A AU2001232081A1 (en) 2000-02-11 2001-02-12 Models, methods and materials relating to clinical conditions associated with reactive oxygen species

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003225.0A GB0003225D0 (en) 2000-02-11 2000-02-11 Models, methods and materials relating to clinical conditions associated with reactive oxygen species

Publications (1)

Publication Number Publication Date
GB0003225D0 true GB0003225D0 (en) 2000-04-05

Family

ID=9885458

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0003225.0A Ceased GB0003225D0 (en) 2000-02-11 2000-02-11 Models, methods and materials relating to clinical conditions associated with reactive oxygen species

Country Status (3)

Country Link
AU (1) AU2001232081A1 (en)
GB (1) GB0003225D0 (en)
WO (1) WO2001058462A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344454T1 (en) * 1996-04-18 2006-11-15 Medical Res Council OXYDATIVE METABOLISM IN SMOOTH MUSCLE CELLS: PROCEDURES RELATED

Also Published As

Publication number Publication date
WO2001058462A2 (en) 2001-08-16
AU2001232081A1 (en) 2001-08-20
WO2001058462A3 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
HK1055446A1 (en) Method for isolation of rna from formalin-fixed paraffin-embedded tissue specimens
ATE551606T1 (en) TISSUE PROCESSOR FOR THE TREATMENT OF HISTOLOGICAL TISSUE PREPARATIONS
ATE266723T1 (en) SOLUTION CONTAINING CHAOTROPIC AGENTS AND USE OF THIS SOLUTION IN PROCEDURES FOR ISOLATION OF DNA, RNA AND PROTEINS
ATE469219T1 (en) COMPOSITIONS, METHODS AND REAGENTS FOR NUCLEIC ACID ISOLATION USING SURFACE-ACTIVE SUBSTANCES AND PROTEASES
DE60216447D1 (en) DEVICE AND METHOD FOR PROCESSING BIOLOGICAL SAMPLES
ATE466957T1 (en) METHODS AND REAGENTS FOR MAINTAINING RNA IN CELLS AND TISSUES
DE3583485D1 (en) IMMUNOGENIC COMPLEX, METHOD FOR THE PRODUCTION AND USE THEREOF AS IMMUNOSTIMULANS, VACCINE AND REAGENTS.
WO2005012879A3 (en) Methods and compositions for preparing tissue samples for rna extraction
IL207923A0 (en) Metal-binding compounds and uses therefor
WO2006065442A3 (en) Methods and compositions for a microemulsion-based tissue treatment
WO2004063704A3 (en) Vitamin d assay
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2002008388A3 (en) Stem cell-like cells
DE50209503D1 (en) PROCESS FOR EXTRACTION AND ANALYSIS OF INGREDIENTS FROM ORGANIC MATERIAL
WO2005042060A3 (en) Method and composition comprising pyruvate, inosine, adenine, phosphate and an aziridino compound for treating a biological sample
IL157917A0 (en) Method for sample identification in a mammal as well as a kit for performing this method
CA2407684A1 (en) Hematology blood control and method for preparation of same
DE60105967D1 (en) Method of extracting oily substances from Ganoderma lucidum spores
GB0003225D0 (en) Models, methods and materials relating to clinical conditions associated with reactive oxygen species
DE50110667D1 (en) Process for the preparation of organosilylalkyl polysulfanes
WO2005017160A3 (en) Mobilization of hematopoietic cells
WO2001048476A3 (en) Extraction of biological components from body fluids
ATE401417T1 (en) CAT PANCREAS LIPASE COMPOSITION AND METHOD FOR PREPARING AND USING SUCH COMPOSITION
WO2002064620A3 (en) Metal-binding compounds and uses therefor
Hasler Flavonoide aus Ginkgo biloba L. und HPLC-Analytik von Flavonoiden in verschiedenen Arzneipflanzen.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)